Zosuquidar

• UNSPSC Description:

  Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research[1][2][3].

• Target Antigen:

  P-glycoprotein

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/zosuquidar.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC1([C@H]2[C@@H]1C3=C([C@@H](C4=CC=CC=C42)N5CCN(CC5)C[C@H](COC6=C7C=CC=NC7=CC=C6)O)C=CC=C3)F

• Molecular Weight:

  527.60

• References & Citations:

  [1]A H Dantzig, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996 Sep 15;56(18):4171-9.|[2]Ruoping Tang, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer. 2008 Feb 13;8:51.|[3]Larry D Cripe, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010 Nov 18;116(20):4077-85.Antiviral Res. 2021 Jun 28;105124.|Biomed Pharmacother. 2020 Sep;129:110506.|Biomed Res Int. 2020 Nov 29;2020:8878158.|bioRxiv. 2024 November 03.|Blood Adv. 2020 Oct 27;4(20):5062-5077.|Cancer Cell. 2017 Apr 10;31(4):501-515.e8. |Crit Rev Anal Chem. 2021 Mar 10;1-15.|Drug Metab Dispos. 2017 May;45(5):449-456.|Exp Ther Med. 2020 Dec 7.|Pharmaceutics. 2021, 13(4), 559.|Biochem Biophys Res Commun. 2021 May.|Biomed Res Int. 2014;2014:850493. |J Chromatogr B Analyt Technol Biomed Life Sci. 2018 May 31;1092:72-81. |J Pharm Biomed Anal. 2012 Jul;66:232-9.|Viruses. 2020 Aug 17;12(8):901.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 3

• CAS Number:

  167354-41-8